Dihydrofolate Reductase Inhibitors (DHFRIs)

About TAXIS Pharmaceuticals

TAXIS Pharmaceuticals is a private, clinical-stage biotech tackling the global antimicrobial resistance (AMR) crisis through a multi-pronged pipeline of novel anti-resistance agents. Its lead asset, TXA709, is an oral FtsZ inhibitor for MRSA that has completed Phase I, while earlier-stage programs target efflux pumps and dihydrofolate reductase for infections like Pseudomonas aeruginosa and drug-resistant gonorrhea. The company leverages non-dilutive funding, such as an NIH grant, and is led by a board with deep pharmaceutical industry experience, positioning it in the high-need but challenging infectious disease therapeutics market.

Therapeutic Areas